Static Chart Summit Therapeutics Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 17:30:11 10/02/2026 GMT			5-day change	1st Jan Change
15.46 ^USD	+3.27%		+5.79%	-11.75%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Duration

Period